Intravenous dolasetron for the prevention of postoperative nausea and vomiting after outpatient laparoscopic gynecologic surgery

Anesthesia and Analgesia

Volumn 84, Issue 2, 1997, Pages 325-330

  Graczyk, Sarena G ^a   McKenzie, Ray ^b   Kallar, Surindar ^c   Hickok, Charles B ^d   Melson, Timothy ^e   Morrill, Bruce ^f   Hahne, William F ^f   Brown, Robert A ^f  

^a Anesthesiologists of Columbia PA   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^e Helen Keller Hospital   (United States)

^f SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ATRACURIUM; DOLASETRON MESILATE; FENTANYL; ISOFLURANE; METHOHEXITAL; NITROUS OXIDE; THIAMYLAL; THIOPENTAL; TUBOCURARINE CHLORIDE;

ADULT; AMBULATORY SURGERY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FEMALE; GYNECOLOGIC SURGERY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LAPAROSCOPIC SURGERY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; PATIENT SATISFACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

ADULT; AMBULATORY SURGICAL PROCEDURES; ANTIEMETICS; DOUBLE-BLIND METHOD; FEMALE; GENITALIA, FEMALE; HUMANS; INDOLES; INJECTIONS, INTRAVENOUS; LAPAROSCOPY; NAUSEA; PATIENT SATISFACTION; POSTOPERATIVE COMPLICATIONS; QUINOLIZINES; VOMITING;

EID: 0031053248     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000539-199702000-00015     Document Type: Article

References (23)

1. Galvan M, Gittos MW, Fatmi M. Dolasetron. Drugs Future 1993;18:506-9.
2. Kris MG, Grunberg SM, Gralla RJ, et al. Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin. J Clin Oncol 1994;12:1045-9.
3. 3 receptors. Drug Dev Res 1993;28:87-93.
4. Yeilding A, Bertoli L, Eisenberg P, et al. Antiemetic efficacy of two different single intravenous doses of dolasetron in patients receiving high-dose cisplatin-containing chemotherapy. Am J Clin Oncol. In press.
5. 3 antagonist, in cancer patients treated with cisplatin. Am J Clin Oncol 1994; 17:97-102.
6. Kasimis BS, Tapazoglou E, Schulman P, et al. A double-blind, randomized study of two different dose regimens of intravenous dolasetron in patients receiving high-dose cisplatin chemotherapy. Cancer Invest. In press.
7. Plezia P, Modiano M, Alberts D, et al. A double-blind, randomized, parallel study of two doses of intravenous (IV) MDL 73,147EF in patients (PTS) receiving high dose cisplatin (CDDP)-containing chemotherapy (CT) [abstract]. Proc Am Soc Clin Oncol 1992;11:407.
8. Watcha MF, White PF. Postoperative nausea and vomiting: its etiology, treatment, and prevention. Anesthesiology 1992;77: 162-84.
9. Camu F, Lauwers MH, Verbessern D. Incidence and aetiology of postoperative nausea and vomiting. Eur J Anaesthesiol 1992; 9(Suppl 6):25-31.
10. 3 antagonists in postoperative nausea and vomiting. Br J Anaesth 1992;69(Suppl 1):63S-68S.
11. Kenny GNC. Risk factors for postoperative nausea and vomiting. Anaesthesia 1994;49(Suppl):6-10.
12. Cooke CE, Mehra IV. Oral ondansetron for preventing nausea and vomiting. Am J Hosp Pharm 1994;51:762-71.
13. Dupeyron JP, Conseiller C, Levarlet M, et al. The effect of oral ondansetron in the prevention of postoperative nausea and vomiting after major gynaecological surgery performed under general anesthesia. Anaesthesia 1993;48:214-8.
14. Helmers JHJH. Oral ondansetron in the prevention of postoperative nausea and vomiting. Eur J Anaesthesiol 1992;9(Suppl 6):49-54.
15. McKenzie R, Kovac A, O'Connor T, et al. Comparison of ondansetron versus placebo to prevent postoperative nausea and vomiting in women undergoing ambulatory gynecologic surgery. Anesthesiology 1993;78:21-8.
16. Rust M, Cohen LA. Single oral dose ondansetron in the prevention of postoperative nausea and emesis. Anaesthesia 1994; 49(Suppl):16-23.
17. 3 receptor antagonists. An overview of their present status and future potential in cancer therapy-induced emesis. Drugs 1991;42:551-68.
18. Del Favero A, Roila F, Tonato M. Reducing chemotherapy-induced nausea and vomiting. Current perspectives and future possibilities. Drug Safety 1993;9:410-28.
19. Hesketh P, Navari R, Grote T, et al. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. J Clin Oncol 1996;14:2242-9.
20. Watanabe H, Hasegawa A, Shinozaki T, et al. Possible cardiac side effects of granisetron, an antiemetic agent, in patients with bone and soft-tissue sarcomas receiving cytotoxic chemotherapy. Cancer Chemother Pharmacol 1995;35:278-82.
21. Audhuy B, Cappelaere P, Martin M, et al. A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesylate and granisetron in patients receiving high-dose cisplatin chemotherapy. Eur J Cancer 1996; 32A:807-13.
22. Hesketh PJ, Gandara DR, Hesketh AM, et al. Dose-ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin or cyclophosphamide. Support Care Cancer 1996;4:141-6.
23. Hirsch J. Impact of postoperative nausea and vomiting in the surgical setting. Anaesthesia 1994;49(Suppl):30-3.